A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia

Angelo M. Carella, Eugenia Gaozza, Gabriell Piatti, Sandro Nati, Ester Pungoltno, Gino Santini, Domenico Giordano, Raffaella Cerri, Marco Risso, Edoardo Rossi, Mauro Spriano, Angela Coingiu, Paolo Carlier, Maria R. Raffo, Eugenio Damagio, Andrea Bacigalupo, Alberto M. Marmont

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5% achieved CR (02.5% in young and 70.3% in old patients) and 40 (71 % after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23% who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients.

Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalLeukemia and Lymphoma
Volume2
Issue number5
DOIs
Publication statusPublished - 1990

Fingerprint

Idarubicin
Cytarabine
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow Transplantation
Tissue Donors
Autologous Transplantation
Homologous Transplantation
Survivors
Leukemia

Keywords

  • ANLL
  • Arac
  • Ldarubicin
  • Leukemia
  • VP 16

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia. / Carella, Angelo M.; Gaozza, Eugenia; Piatti, Gabriell; Nati, Sandro; Pungoltno, Ester; Santini, Gino; Giordano, Domenico; Cerri, Raffaella; Risso, Marco; Rossi, Edoardo; Spriano, Mauro; Coingiu, Angela; Carlier, Paolo; Raffo, Maria R.; Damagio, Eugenio; Bacigalupo, Andrea; Marmont, Alberto M.

In: Leukemia and Lymphoma, Vol. 2, No. 5, 1990, p. 317-322.

Research output: Contribution to journalArticle

Carella, AM, Gaozza, E, Piatti, G, Nati, S, Pungoltno, E, Santini, G, Giordano, D, Cerri, R, Risso, M, Rossi, E, Spriano, M, Coingiu, A, Carlier, P, Raffo, MR, Damagio, E, Bacigalupo, A & Marmont, AM 1990, 'A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia', Leukemia and Lymphoma, vol. 2, no. 5, pp. 317-322. https://doi.org/10.3109/10428199009106467
Carella, Angelo M. ; Gaozza, Eugenia ; Piatti, Gabriell ; Nati, Sandro ; Pungoltno, Ester ; Santini, Gino ; Giordano, Domenico ; Cerri, Raffaella ; Risso, Marco ; Rossi, Edoardo ; Spriano, Mauro ; Coingiu, Angela ; Carlier, Paolo ; Raffo, Maria R. ; Damagio, Eugenio ; Bacigalupo, Andrea ; Marmont, Alberto M. / A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia. In: Leukemia and Lymphoma. 1990 ; Vol. 2, No. 5. pp. 317-322.
@article{1ee4a374e7144bf5ab000e5f3cacf4bb,
title = "A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia",
abstract = "Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5{\%} achieved CR (02.5{\%} in young and 70.3{\%} in old patients) and 40 (71 {\%} after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23{\%} who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients.",
keywords = "ANLL, Arac, Ldarubicin, Leukemia, VP 16",
author = "Carella, {Angelo M.} and Eugenia Gaozza and Gabriell Piatti and Sandro Nati and Ester Pungoltno and Gino Santini and Domenico Giordano and Raffaella Cerri and Marco Risso and Edoardo Rossi and Mauro Spriano and Angela Coingiu and Paolo Carlier and Raffo, {Maria R.} and Eugenio Damagio and Andrea Bacigalupo and Marmont, {Alberto M.}",
year = "1990",
doi = "10.3109/10428199009106467",
language = "English",
volume = "2",
pages = "317--322",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia

AU - Carella, Angelo M.

AU - Gaozza, Eugenia

AU - Piatti, Gabriell

AU - Nati, Sandro

AU - Pungoltno, Ester

AU - Santini, Gino

AU - Giordano, Domenico

AU - Cerri, Raffaella

AU - Risso, Marco

AU - Rossi, Edoardo

AU - Spriano, Mauro

AU - Coingiu, Angela

AU - Carlier, Paolo

AU - Raffo, Maria R.

AU - Damagio, Eugenio

AU - Bacigalupo, Andrea

AU - Marmont, Alberto M.

PY - 1990

Y1 - 1990

N2 - Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5% achieved CR (02.5% in young and 70.3% in old patients) and 40 (71 % after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23% who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients.

AB - Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5% achieved CR (02.5% in young and 70.3% in old patients) and 40 (71 % after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23% who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients.

KW - ANLL

KW - Arac

KW - Ldarubicin

KW - Leukemia

KW - VP 16

UR - http://www.scopus.com/inward/record.url?scp=0025611736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025611736&partnerID=8YFLogxK

U2 - 10.3109/10428199009106467

DO - 10.3109/10428199009106467

M3 - Article

VL - 2

SP - 317

EP - 322

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -